Otitopic Inc.

Our mission is to provide patients with a faster alternative for management of suspected myocardial infarction (MI). OtiTopic, Inc., founded in 2012, is a late-stage clinical pharmaceutical company, with a track record of success in product drug delivery and drug device development. OtiTopic has changed the route of administration of Aspirin and is on track to file an NDA for commercialization and marketing in the US. OtiTopic has developed a dry powder inhalation of aspirin for suspected acute MI patients that enters the bloodstream in less than two minutes. By exploiting the respiratory system as a speedy route of administration, ASPRIHALE® could revolutionize the rapid and complete platelet inhibition and PD effects for suspected acute MI patients, becoming the first non-invasive and heart-specific therapy after FDA approval. To improve prognosis during the pre-hospital period, small differences in the timing of aspirin and fibrinolytic administration were both major determinants to survival in acute MI patients. Once a fibrin fiber-rich thrombus is formed, it is less responsive to antithrombotic therapy and requires an adjunctive mechanical treatment by percutaneous coronary intervention. In the treatment of acute myocardial infarction (MI) the time to treatment is important, suggesting that small differences in time to reducing ischemia make clinically important differences in mortality. Within the first few minutes of symptoms, time to treatment is critical, as there is a striking benefit to quickly achieving reperfusion. Studies have shown “The relationship between reduction of ischemic time and subsequent mortality was demonstrated to be nonlinear and decreases rapidly with time, highlighting the need for a rapid antithrombotic treatment as soon as possible after symptom onset”.